Ignite Creation Date:
2025-12-24 @ 7:15 PM
Ignite Modification Date:
2026-02-19 @ 7:00 AM
Study NCT ID:
NCT02730403
Status:
COMPLETED
Last Update Posted:
2020-03-27
First Post:
2016-03-21
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009293', 'term': 'Opioid-Related Disorders'}], 'ancestors': [{'id': 'D000079524', 'term': 'Narcotic-Related Disorders'}, {'id': 'D019966', 'term': 'Substance-Related Disorders'}, {'id': 'D064419', 'term': 'Chemically-Induced Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D013812', 'term': 'Therapeutics'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'john.rotrosen@nyulangone.org', 'phone': '646-754-4763', 'title': 'John Rotrosen', 'organization': 'NYU Grossman School of Medicine'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'timeFrame': '9 month', 'description': 'For purposes of this study, only overdoses (whether hospitalized or not) and all deaths were collected. The relationship of adverse event was only collected for overdose events.', 'eventGroups': [{'id': 'EG000', 'title': 'Treatment As Usual', 'description': 'Patients who were admitted to detoxification or short term residential programs associated with CTN-0051 with OUD.', 'otherNumAtRisk': 211, 'deathsNumAtRisk': 211, 'otherNumAffected': 8, 'seriousNumAtRisk': 211, 'deathsNumAffected': 1, 'seriousNumAffected': 7}], 'otherEvents': [{'term': 'Overdose', 'stats': [{'groupId': 'EG000', 'numAtRisk': 211, 'numEvents': 12, 'numAffected': 8}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'seriousEvents': [{'term': 'Overdose', 'stats': [{'groupId': 'EG000', 'numAtRisk': 211, 'numEvents': 7, 'numAffected': 7}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Days of Opioid Use', 'denoms': [{'units': 'Participants', 'counts': [{'value': '211', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment As Usual', 'description': 'Patients admitted to detoxification or short term residential associated with CTN-0051 for OUD.'}], 'classes': [{'categories': [{'measurements': [{'value': '6.8', 'spread': '8.95', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Up to Week 4 Post Discharge', 'description': 'Days of use during the first 4 weeks post discharge', 'unitOfMeasure': 'days', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Positive Urine Drug Screen (UDS) at Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '211', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment As Usual', 'description': 'Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.'}], 'classes': [{'categories': [{'measurements': [{'value': '106', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'week 1', 'description': 'Number of positive UDSs at Week 1', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Negative UDSs at Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '211', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment As Usual', 'description': 'Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.'}], 'classes': [{'categories': [{'measurements': [{'value': '60', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'week 1', 'description': 'Number of negative UDSs at Week 1', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Missing UDSs at Week 1', 'denoms': [{'units': 'Participants', 'counts': [{'value': '211', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment As Usual', 'description': 'Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.'}], 'classes': [{'categories': [{'measurements': [{'value': '45', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'week 1', 'description': 'Number of missing UDSs at Week 1', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Missing UDSs at Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '211', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment As Usual', 'description': 'Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.'}], 'classes': [{'categories': [{'measurements': [{'value': '54', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'week 4', 'description': 'Number of missing UDSs at Week 4', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Positive UDSs at Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '211', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment As Usual', 'description': 'Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.'}], 'classes': [{'categories': [{'measurements': [{'value': '102', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'week 4', 'description': 'Number of positive UDSs at Week 4', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Negative UDSs at Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'value': '211', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment As Usual', 'description': 'Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.'}], 'classes': [{'categories': [{'measurements': [{'value': '55', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'week 4', 'description': 'Number of negative UDSs at Week 4', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Missing UDSs at Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '211', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment As Usual', 'description': 'Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.'}], 'classes': [{'categories': [{'measurements': [{'value': '55', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'week 8', 'description': 'Number of missing UDSs at Week 8', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Negative UDSs at Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '211', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment As Usual', 'description': 'Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.'}], 'classes': [{'categories': [{'measurements': [{'value': '66', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'week 8', 'description': 'Number of negative UDSs at Week 8', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Positive UDSs at Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '211', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment As Usual', 'description': 'Patients admitted to detoxification or short term residential treatment programs associated with CTN-0051 with OUD.'}], 'classes': [{'categories': [{'measurements': [{'value': '90', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'week 8', 'description': 'Number of positive UDSs at Week 8', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Time to First Use', 'denoms': [{'units': 'Participants', 'counts': [{'value': '211', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment As Usual', 'description': 'Patients admitted to detoxification or short term residential associated with CTN-0051 for OUD.'}], 'classes': [{'categories': [{'measurements': [{'value': '7.5', 'spread': '10.17', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Up to Week 8 Post Discharge', 'description': 'Days to first opioid use from Timeline Followback', 'unitOfMeasure': 'days', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Patients admitted to detoxification or short term residential programs associated with CTN-0051 for OUD'}, {'type': 'PRIMARY', 'title': 'Time to Regular Use', 'denoms': [{'units': 'Participants', 'counts': [{'value': '211', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment As Usual', 'description': 'Patients admitted to detoxification or short term residential associated with CTN-0051 for OUD.'}], 'classes': [{'categories': [{'measurements': [{'value': '11.3', 'spread': '11.58', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Up to Week 8 Post Discharge', 'description': 'Days to regular opioid use from Timeline Followback', 'unitOfMeasure': 'days', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Patients admitted to detoxification or short term residential programs associated with CTN-0051 for OUD'}, {'type': 'PRIMARY', 'title': 'Days of Opioid Use', 'denoms': [{'units': 'Participants', 'counts': [{'value': '211', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Treatment As Usual', 'description': 'Patients admitted to detoxification or short term residential associated with CTN-0051 for OUD.'}], 'classes': [{'categories': [{'measurements': [{'value': '13.2', 'spread': '16.7', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Up to Week 8 Post Discharge', 'description': 'Days of use up 8 weeks post discharge', 'unitOfMeasure': 'days', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Treatment As Usual', 'description': 'Patients admitted to detoxification or short term residential programs associated with CTN-0051 for Opioid Use Disorder (OUD).'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '211'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '157'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '54'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '211', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Treatment As Usual', 'description': 'Patients admitted to detoxification or short term residential programs associated with CTN-0051 with OUD.'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '211', 'groupId': 'BG000'}]}, {'title': '>=65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '35', 'spread': '9.48', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Age, Customized', 'classes': [{'title': '18 - <25', 'categories': [{'measurements': [{'value': '23', 'groupId': 'BG000'}]}]}, {'title': '25 - <35', 'categories': [{'measurements': [{'value': '96', 'groupId': 'BG000'}]}]}, {'title': '35 - <45', 'categories': [{'measurements': [{'value': '52', 'groupId': 'BG000'}]}]}, {'title': '45 - <55', 'categories': [{'measurements': [{'value': '33', 'groupId': 'BG000'}]}]}, {'title': '55 - <65', 'categories': [{'measurements': [{'value': '7', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '55', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '156', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '37', 'groupId': 'BG000'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '172', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '2', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'title': 'Race', 'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '4', 'groupId': 'BG000'}]}, {'title': 'Asian', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'Black or African American', 'measurements': [{'value': '28', 'groupId': 'BG000'}]}, {'title': 'White', 'measurements': [{'value': '143', 'groupId': 'BG000'}]}, {'title': 'More than one race', 'measurements': [{'value': '10', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '24', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '211', 'groupId': 'BG000'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'Baseline Opioid Severity', 'classes': [{'categories': [{'title': 'Low', 'measurements': [{'value': '110', 'groupId': 'BG000'}]}, {'title': 'High', 'measurements': [{'value': '101', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2016-08-05', 'size': 360840, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2020-02-21T08:26', 'hasProtocol': True}, {'date': '2017-04-26', 'size': 485717, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2020-02-21T08:38', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'OTHER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 211}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-06-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-03', 'completionDateStruct': {'date': '2017-01-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-03-17', 'studyFirstSubmitDate': '2016-03-21', 'resultsFirstSubmitDate': '2020-03-04', 'studyFirstSubmitQcDate': '2016-03-31', 'lastUpdatePostDateStruct': {'date': '2020-03-27', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2020-03-04', 'studyFirstPostDateStruct': {'date': '2016-04-06', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2020-03-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-01-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Days of Opioid Use', 'timeFrame': 'Up to Week 4 Post Discharge', 'description': 'Days of use during the first 4 weeks post discharge'}, {'measure': 'Positive Urine Drug Screen (UDS) at Week 1', 'timeFrame': 'week 1', 'description': 'Number of positive UDSs at Week 1'}, {'measure': 'Negative UDSs at Week 1', 'timeFrame': 'week 1', 'description': 'Number of negative UDSs at Week 1'}, {'measure': 'Missing UDSs at Week 1', 'timeFrame': 'week 1', 'description': 'Number of missing UDSs at Week 1'}, {'measure': 'Missing UDSs at Week 4', 'timeFrame': 'week 4', 'description': 'Number of missing UDSs at Week 4'}, {'measure': 'Positive UDSs at Week 4', 'timeFrame': 'week 4', 'description': 'Number of positive UDSs at Week 4'}, {'measure': 'Negative UDSs at Week 4', 'timeFrame': 'week 4', 'description': 'Number of negative UDSs at Week 4'}, {'measure': 'Missing UDSs at Week 8', 'timeFrame': 'week 8', 'description': 'Number of missing UDSs at Week 8'}, {'measure': 'Negative UDSs at Week 8', 'timeFrame': 'week 8', 'description': 'Number of negative UDSs at Week 8'}, {'measure': 'Positive UDSs at Week 8', 'timeFrame': 'week 8', 'description': 'Number of positive UDSs at Week 8'}, {'measure': 'Time to First Use', 'timeFrame': 'Up to Week 8 Post Discharge', 'description': 'Days to first opioid use from Timeline Followback'}, {'measure': 'Time to Regular Use', 'timeFrame': 'Up to Week 8 Post Discharge', 'description': 'Days to regular opioid use from Timeline Followback'}, {'measure': 'Days of Opioid Use', 'timeFrame': 'Up to Week 8 Post Discharge', 'description': 'Days of use up 8 weeks post discharge'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'conditions': ['Opioid Use Disorder']}, 'descriptionModule': {'briefSummary': 'This is an observational, "ancillary study" intended to describe opioid use among opioid use disorder patients following their discharge into the community from inpatient detoxification and/or short-term residential treatment programs affiliated with parent study CTN-0051, which assessed the comparative effectiveness of extended release injectable naltrexone (XR-NTX, Vivitrol®), an opioid antagonist recently approved and indicated for the prevention of relapse to opioid dependence, versus buprenorphine-naloxone (BUP-NX, Suboxone®), a high affinity partial agonist indicated for maintenance treatment of opioid dependence, as pharmacotherapeutic aids to recovery.', 'detailedDescription': 'Participant recruitment will begin after recruitment for CTN-0051 has been completed. Opioid use disorder patients will be recruited prior to leaving detoxification and/or short-term residential programs. Screening and baseline data (focused on demographics, diagnosis and service utilization) will be collected prior to discharge, and follow-up data (focused on opioid use) will be collected at weeks 1, 4 and 8 following discharge.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Participants will be a convenience sample of up to three hundred sixty (360) opioid dependent patients leaving detoxification or short-term residential units at sites participating in CTN-0051. Up to 60 participants will be recruited at each of approximately six sites.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* 18 years or older;\n* Meet DSM-5 criteria for opioid-use disorder (heroin or prescription opioids);\n* Have used opioids other than as specifically prescribed within thirty days prior to consent\n* Seeking treatment for opioid dependence;\n* Able to provide written informed consent;\n* Able to speak English sufficiently to understand the study procedures.\n\nExclusion Criteria:\n\n* Serious medical, psychiatric or substance use disorder that, in the opinion of the Site PI, would make participation hazardous to the participant, compromise study findings or prevent the participant from completing the study;\n* Suicidal or homicidal ideation that requires immediate attention;\n* Maintenance on methadone at doses of 30mg or greater at the time of signing consent;\n* Presence of pain of sufficient severity as to require ongoing pain management with opioids;\n* Pending legal action or other reasons that might prevent an individual from completing the study;\n* If female, currently pregnant or breastfeeding or planning on conception;\n* Prior participation in parent trial CTN-0051'}, 'identificationModule': {'nctId': 'NCT02730403', 'briefTitle': 'TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051', 'organization': {'class': 'OTHER', 'fullName': 'NYU Langone Health'}, 'officialTitle': 'Treatment-as-Usual (TAU) Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With National Institute on Drug Abuse (NIDA) CTN-0051', 'orgStudyIdInfo': {'id': '16-00090'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Opioid Use Disorder Patients', 'interventionNames': ['Other: Treatment As Usual']}], 'interventions': [{'name': 'Treatment As Usual', 'type': 'OTHER', 'armGroupLabels': ['Opioid Use Disorder Patients']}]}, 'contactsLocationsModule': {'locations': [{'zip': '91356', 'city': 'Tarzana', 'state': 'California', 'country': 'United States', 'facility': 'Tarzana Treatment Centers', 'geoPoint': {'lat': 34.17334, 'lon': -118.55397}}, {'zip': '32201', 'city': 'Jacksonville', 'state': 'Florida', 'country': 'United States', 'facility': 'Gateway Community Services, Inc.', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'zip': '02720', 'city': 'Fall River', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Stanley Street Treatment and Resources', 'geoPoint': {'lat': 41.70149, 'lon': -71.15505}}, {'zip': '10016', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Bellevue Hospital', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '43207', 'city': 'Columbus', 'state': 'Ohio', 'country': 'United States', 'facility': 'Maryhaven', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}], 'overallOfficials': [{'name': 'John Rotrosen, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'New York University Medical School'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'NYU Langone Health', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}